(Reuters) -The U.S. Food and Drug Administration said on Thursday it has awarded six more companies, including Eli Lilly and Novo Nordisk, special vouchers that will speed up the review of their medicines, bringing the total number of recipients to 15.

The vouchers went to treatments for cancer, obesity, tuberculosis and sickle cell disease.

The recipients include Novo’s weight-loss drug Wegovy, Lilly’s experimental obesity pill orforglipron, and Vertex Pharmaceuticals’ gene therapy Casgevy for sickle cell disease.

Also selected were: GSK’s dostarlimab for rectal cancer, Takeda Pharmaceutical’s bedaquiline for drug-resistant tuberculosis in young children, and BeiGene’s zongertinib for a type of lung cancer.

The vouchers are part of a pilot program called the Commissioner’s National Pr

See Full Page